The key differentiator of our commercialization solutions lies in an understanding that the paradigm by which biopharma products reach the market has fundamentally changed. Many Asia-Pacific markets are growing in importance on the global scene, while the US and European markets have stagnated. Developing commercialization solutions to meet the needs of the healthcare market in the Asia-Pacific region can be more cost effective and may benefit a larger population.
"... Where does William fit in?" Good question, Guardiangel.
Since its apparent this has been a well orchestrated Takeover that has been in the making for some time now- what is the actual relationship between Provista/William Gartner and Mr. Charter/BOD.
Who is the Primary Owner of RXPC? Mr. Charter is one of the Takeover Group. I wonder what the actual share ownership breakdown is within the Group itself- equal shares spread out or not?
News 
Market Data 
Discover 
AI
